Alector (ALEC) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $3.3M
- Gross margin
- 100.00%
- Net income (quarter)
- −$23.0M
- Net margin
- −850.13%
- Return on equity
- −385.11%
- Book value per share
- −$0.09
- Debt to assets
- 104.91%
Company profile
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Frequently asked questions
Is Alector (ALEC) profitable?
No. Alector reported a net loss of $117.9M over the trailing twelve months.
How much revenue does Alector (ALEC) make?
Alector generated $13.9M in revenue over the trailing twelve months, down 57.84% year over year.
How do I buy stock in Alector (ALEC)?
ALEC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.